Published in PLoS One on February 25, 2010
Identification of a cell of origin for human prostate cancer. Science (2010) 6.33
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell (2012) 2.84
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest (2012) 1.63
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol (2015) 1.45
AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res (2014) 1.29
Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis (2013) 1.17
Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene. Am J Pathol (2011) 1.12
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene (2011) 1.10
Molecular pathogenesis and progression of prostate cancer. Semin Oncol (2013) 1.08
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol (2012) 0.96
RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis. Cancer Discov (2014) 0.93
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Current mouse and cell models in prostate cancer research. Endocr Relat Cancer (2013) 0.92
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. Am J Clin Exp Urol (2014) 0.91
Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One (2014) 0.90
The diet as a cause of human prostate cancer. Cancer Treat Res (2014) 0.86
Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTEN. Mol Cancer (2013) 0.85
Histone H2A.Z deregulation in prostate cancer. Cause or effect? Cancer Metastasis Rev (2014) 0.84
The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis (2013) 0.84
Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1. J Biol Chem (2012) 0.82
Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. Int J Clin Exp Pathol (2014) 0.82
Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells. Biochim Biophys Acta (2011) 0.81
4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. J Histochem Cytochem (2013) 0.80
Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer (2014) 0.79
Optimizing mouse models for precision cancer prevention. Nat Rev Cancer (2016) 0.77
USP2a activation of MYC in prostate cancer. Cancer Discov (2012) 0.77
RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis. Am J Pathol (2013) 0.77
Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer. Cancer Res (2015) 0.77
Lack of an additive effect between the deletions of Klf5 and Nkx3-1 in mouse prostatic tumorigenesis. J Genet Genomics (2013) 0.76
c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells. Cell Cycle (2016) 0.75
Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem (2016) 0.75
A basal cell defect promotes budding of prostatic intraepithelial neoplasia. J Cell Sci (2016) 0.75
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes (Basel) (2017) 0.75
miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth. Oncotarget (2017) 0.75
SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Oncogene (2017) 0.75
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Recombineering: a powerful new tool for mouse functional genomics. Nat Rev Genet (2001) 8.35
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
MYC oncogenes and human neoplastic disease. Oncogene (1999) 7.28
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
The c-Myc target gene network. Semin Cancer Biol (2006) 5.98
Prostate cancer. N Engl J Med (2003) 5.91
A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature (2009) 5.65
Genetic transformation of mouse embryos by microinjection of purified DNA. Proc Natl Acad Sci U S A (1980) 5.47
Maximizing mouse cancer models. Nat Rev Cancer (2007) 5.38
Molecular genetics of prostate cancer. Genes Dev (2000) 5.18
Remote control of gene transcription. Hum Mol Genet (2005) 4.80
Myc influences global chromatin structure. EMBO J (2006) 4.71
Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Metastatic prostate cancer in a transgenic mouse. Cancer Res (1996) 4.02
Generation of a prostate from a single adult stem cell. Nature (2008) 3.46
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A (2008) 3.26
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Apoptotic signaling by c-MYC. Oncogene (2008) 2.57
Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol (2002) 2.48
c-Myc promotes differentiation of human epidermal stem cells. Genes Dev (1997) 2.37
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res (2000) 2.13
Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell (2009) 2.10
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res (1992) 1.98
Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell (2008) 1.86
Prostate-specific and androgen-dependent expression of a novel homeobox gene. J Biol Chem (1996) 1.85
Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol (2002) 1.83
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
A new vector for recombination-based cloning of large DNA fragments from yeast artificial chromosomes. Nucleic Acids Res (1995) 1.80
The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate (1994) 1.79
Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Res (2006) 1.76
Stem cells in prostate cancer initiation and progression. J Clin Invest (2007) 1.76
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol (2003) 1.65
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res (2001) 1.59
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate (2005) 1.57
Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res (2005) 1.57
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation (2008) 1.55
N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. Cancer Res (2008) 1.52
Integrative biology of prostate cancer progression. Annu Rev Pathol (2006) 1.45
Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell (2003) 1.38
Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res (2005) 1.30
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene (2009) 1.28
Nkx3.1, a murine homolog of Ddrosophila bagpipe, regulates epithelial ductal branching and proliferation of the prostate and palatine glands. Dev Dyn (2000) 1.27
Myc goes global: new tricks for an old oncogene. Cancer Res (2007) 1.27
Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res (1986) 1.25
Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol (2007) 1.24
Roles of the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn (2003) 1.23
Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia (2007) 1.22
Molecular biology of prostatic intraepithelial neoplasia. Prostate (1996) 1.22
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol (2000) 1.22
Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol (1994) 1.21
Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res (2009) 1.20
Targeted disruption of the Nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate. Mech Dev (2000) 1.17
Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet (2009) 1.16
Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate (1997) 1.15
Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells (2007) 1.14
Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate (2000) 1.12
Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS One (2009) 1.08
Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol (1997) 1.07
Distinct regulatory elements mediate the dynamic expression pattern of Nkx3.1. Dev Dyn (2005) 1.04
Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesis. J Urol (2004) 1.04
Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. Cancer Res (2008) 1.02
Molecular pathways to prostate cancer. J Urol (2003) 0.98
Cell proliferation in dysplasia of the prostate: analysis by PCNA immunostaining. Prostate (1995) 0.98
NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells. Mol Cell Biol (2006) 0.96
Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod Pathol (1996) 0.96
Molecular genetics of prostate cancer. Ann Med (2001) 0.93
Precursor lesions to prostatic adenocarcinoma. Virchows Arch (2008) 0.92
Current practice of diagnosis and reporting of prostatic intraepithelial neoplasia and glandular atypia among genitourinary pathologists. Mod Pathol (2006) 0.89
Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol (1988) 0.84
Ratcheting Myc. Cancer Cell (2008) 0.81
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature (2009) 13.28
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer (2011) 9.68
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Cancer's molecular sweet tooth and the Warburg effect. Cancer Res (2006) 7.24
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell (2007) 6.06
Prostate cancer. N Engl J Med (2003) 5.91
Tracking the clonal origin of lethal prostate cancer. J Clin Invest (2013) 5.79
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell (2010) 5.02
Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol (2005) 4.99
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab (2012) 4.80
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol (2007) 3.51
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res (2010) 3.30
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
Multifaceted roles of glycolytic enzymes. Trends Biochem Sci (2005) 3.01
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget (2011) 2.80
A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov (2011) 2.77
Epidemiology of inflammation and prostate cancer. J Urol (2004) 2.76
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Prostate cancer and inflammation: the evidence. Histopathology (2012) 2.60
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res (2009) 2.39
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab (2007) 2.36
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis (2004) 2.33
The role of inflammation in the pathogenesis of prostate cancer. J Urol (2004) 2.29
Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res (2002) 2.24
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther (2010) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol (2004) 2.19
Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate (2009) 2.17
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab (2003) 2.16
Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS One (2008) 2.12
Accurate genome-scale percentage DNA methylation estimates from microarray data. Biostatistics (2010) 2.11
DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res (2008) 2.08
Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care (2007) 2.08
A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate (2008) 2.04
Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A (2012) 2.02
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 2.01
Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 2.00
Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol (2002) 1.95
XMRV: a new virus in prostate cancer? Cancer Res (2010) 1.95
A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res (2012) 1.92
p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biol Ther (2004) 1.90
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
Procainamide is a specific inhibitor of DNA methyltransferase 1. J Biol Chem (2005) 1.84
MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol Ther (2004) 1.82
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79